Synonyms: Amglidia® | Diabeta® | glyburide | Glynase®
glibenclamide is an approved drug (FDA (as glyburide, 1984), EMA (2018))
Compound class:
Synthetic organic
Comment: A sulfonylurea family drug inhibiting sulfonylurea receptor 1 (ABCC8)/Kir6.2 (KCNJ11). Glibenclamide induced blockade of SUR1-TRPM4 channels reduces inflammatory markers and improves clinical symptoms in mouse experimental autoimmune encephalomyelitis (EAE), and may be of relevance in multiple sclerosis as SUR1-TRPM4-expressing lesions from MS provide a potentially disease modiifying target [12].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖View more information in the IUPHAR Pharmacology Education Project: glibenclamide |
|
Immunopharmacology Comments |
Glibenclamide has been reported to block NLRP3 inflammasome activation in vitro, and delay LPS-induced lethality in vivo [27]. |